Bepranemab

DRUG4 trials

Sponsors

UCB Biopharma, UCB Biopharma SRL

Conditions

Alzheimer's DiseaseAlzheimer’s DiseaseProgressive Supranuclear Palsy

Phase 1

A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)

CompletedNCT04185415

UCB Biopharma SRLProgressive Supranuclear Palsy

Start: 2019-12-03End: 2021-11-17Updated: 2023-12-01

An Open-Label Extension Study to Evaluate the Safety and Tolerability of Long-Term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy

Active, not recruitingCTIS2024-510951-36-00

UCB BiopharmaProgressive Supranuclear Palsy

Start: 2020-11-16Target: 17Updated: 2025-07-25

Phase 2

A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

CompletedNCT04867616

UCB Biopharma SRLAlzheimer's Disease

Start: 2021-06-09End: 2025-08-01Updated: 2025-08-29

A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer’s Disease (AD), Followed by an Open-Label Extension Period

CompletedCTIS2023-506170-12-00

UCB BiopharmaAlzheimer’s Disease

Start: 2021-10-18End: 2025-08-01Target: 251Updated: 2025-09-08

Related Papers

Tau positron emission tomography results from TOGETHER, a double‐blind, placebo‐controlled Phase II study of bepranemab in prodromal–mild Alzheimer’s disease

Alzheimer s & Dementia2025-12-01

Establishing bepranemab posology through exposure‐response modeling and simulation for TOGETHER, a double‐blind, placebo‐controlled Phase II study of bepranemab in prodromal–mild Alzheimer’s disease (AD)

Alzheimer s & Dementia2025-12-01

Effect of an 18-month meditation training on cardiovascular risk in older adults: a secondary analysis of the Age-Well randomized controlled trial.

2024-11-16

Reliability of the assessment of the clinical dementia rating scale from the analysis of medical records in comparison with the reference method.

2024-09-0510 citations

Update on the TOGETHER study: a patient‐ and investigator‐blind, randomized, placebo‐controlled study evaluating the efficacy, safety and tolerability of bepranemab, UCB0107, in prodromal‐to‐mild Alzheimer’s disease

Alzheimer s & Dementia2022-12-014 citations

Baseline [<sup>18</sup>F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer's disease.

2021-12-0120 citations

Design of a patient‐ and investigator‐blind, randomized, placebo‐controlled study to evaluate efficacy, safety, and tolerability of bepranemab, UCB0107, in prodromal to mild Alzheimer’s disease: The TOGETHER Study, AH0003

Alzheimer s & Dementia2021-12-011 citations

Does the Anti‐Tau Strategy in Progressive Supranuclear Palsy Need to Be Reconsidered? <scp>No</scp>

Movement Disorders Clinical Practice2021-08-075 citations